Expediting Development of Rare Disease Therapies for the Public Good
Contact Us: service@regalintel.com
Expediting Development of Rare Disease Therapies for the Public Good
Contact Us: service@regalintel.com
The AI Research Accelerator
Your Data Stays. The Insights Flow.
We are the specialized 501(c)(3) non-profit partner solving the crisis of data sparsity by leveraging our exclusive Synthetic Patient Twin (SPT) Engine to generate regulatory-grade RWE from unstructured clinical records.
The RWE Challenge We Solve
We specialize in navigating the intricate regulatory pathway for ultra-rare conditions where traditional Randomized Controlled Trials (RCTs) are often infeasible. Our expertise lies in transforming fragmented clinical and genetic data into regulatory-grade RWE that supports expedited development processes across all phases.
The RWE Challenge We Solve
We specialize in navigating the intricate regulatory pathway for ultra-rare conditions where traditional Randomized Controlled Trials (RCTs) are often infeasible. Our expertise lies in transforming fragmented clinical and genetic data into regulatory-grade RWE that supports expedited development processes across all phases.
Closing the Data Gap: Our Triple Advantage
AI & Phenotype Extraction (NLP)
AI & Phenotype Extraction (NLP)
AI & Phenotype Extraction (NLP)
We deploy proprietary Natural Language Processing (NLP) to extract metrics like CC Scores and Genotype Variants—data trapped in clinical text—to enable precision patient stratification.
Secure Distributed Model
AI & Phenotype Extraction (NLP)
AI & Phenotype Extraction (NLP)
Our AI executes within your secure firewall (Bring the Algorithm to the Data), guaranteeing HIPAA/GDPR compliance and eliminating centralized data transfer risk.
Mutual Data Enrichment
AI & Phenotype Extraction (NLP)
Mutual Data Enrichment
The structured variables extracted by our AI are shared back with our data partners, permanently enriching your internal data asset for future research.
Representative Focus
Synthetic Control Arms (SCA)
Synthetic Control Arms (SCA)
Synthetic Control Arms (SCA)
Generate high-fidelity control groups for single-arm trials (Oncology/Rare Disease) to support regulatory submissions.
Genotype-Risk Modeling
Synthetic Control Arms (SCA)
Synthetic Control Arms (SCA)
Provide STK11 and Trisomy 6q risk models for precision surveillance and trial inclusion criteria.
Commercial Strategy RWE
Synthetic Control Arms (SCA)
Commercial Strategy RWE
Quantify **Time-to-Diagnosis (TTD)** metrics for market sizing and patient awareness campaigns.